PPT-The ABCs of AF Goals Bleeding With Warfarin

How Frequent Is Bleeding With NOACs Bleeding Risk HASBLED Bleeding Scores in AF Biomarkers in AF Reasons for and Implications of Elevated GDF15 Level GDF15 in ARISTOTLE GDF15 Strongest Bleeding Marker. Andrew McDonald. Alberts Cellular Therapy. “All bleeding eventually stops”. n. Modified Virchow’s triad. BLEEDING. Blood flow. Size. BP. Vessel wall. Endothelial activation. Collagen disorders. Eliot Williams, MD PhD. Division of Hematology & Medical Oncology. Nothing to disclose. History of anticoagulant therapy. 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010. Allyson Sarigianis, Pharm.D.. October 19, 2013. Objectives. Review current practice recommendations for prevention of stroke/systemic embolism in atrial fibrillation. Compare and contrast pharmacology between warfarin and target specific oral anticoagulants (TSOACs). (. N. OAC). Dan . Moellentin. , . PharmD. , BCPS, Associate Professor . Husson. University. Strokes in Atrial Fibrillation. 1/5 of strokes are caused by a. fib. 1/3 cardiac arrhythmias hospitalizations . Atrial. Fibrillation. Phillip H. Lam, M.D.. Chief Medical Resident. Medstar. Georgetown University Hospital. Disclosure. None. Disclosure. None. Disclosure. I am not a cardiologist. General medicine perspective. Eliot Williams, MD PhD. Division of Hematology & Medical Oncology. History of anticoagulant therapy. 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010. st. century: A practical guide to using newer Agents. Katherine Vogel Anderson, . Pharm.D. ., BCACP. University of Florida Colleges of Pharmacy and Medicine. Disclosures . I have nothing to disclose. Dabigatran . Etexilate versus Warfarin in Patients Undergoing . Catheter . Ablation of Atrial Fibrillation: . The RE-CIRCUIT™ . Study. Hugh Calkins, . M.D.,. 1. Stephan . Willems. , M.D., Atul . Verma. Definition of Anticoagulation. Therapeutic interference with the clotting mechanism of the blood . ("blood-thinning") to . prevent or treat thrombosis and embolism.. Indications of Anticoagulant Therapy. Pharm.D. .. Edoxaban. Oral factor . Xa. inhibitor. Bioavailability: 62%. Tmax. : 1-2 hrs. Elimination: 50% renal. Half-life: 9-11 hours. ENGAGE AF-TIMI 48. Randomized, double-blind, double-dummy trial. June 12, 2009. Internal Medicine Morning Report. Sally Ravanos, MD. MKSAP Question #1. A 51yo woman with chronic low back pain is evaluated for a 2-week history of moderate low back pain radiating down her right leg to her right foot following a paroxysm of sneezing. She has no leg weakness or numbness. She is on no meds, and her medical history is only significant for a hysterectomy.. www.onlinecjc.com. ). .  . If your reuse request qualifies as medical institution internal education, you may reuse the material under the following conditions:. You must cite the Canadian Journal of Cardiology and the Canadian Cardiovascular Society as references.. Dr NA Smith - Haematology Dept. Heart of England NHS Foundation Trust. Venous . thromboembolism. (VTE). Venous Ulcers. . PE . DVT . Post-thrombotic. syndrome. Death. . Deep vein . insufficiency. Received January 25, 1999, from the Department of Obstetrics andGynecology, Faculty of Medicine, Chiang Mai University, ChiangMai, Thailand. Revised manuscript accepted for publication April 4,Address